The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax's COVID-19 vaccine, but only for certain ...

The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition. The approval is based on ...

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect ...

Novavax had expected full approval for broader use by April 1, after the FDA reviewed data from a 30,000-person clinical ...

The Food and Drug Administration will soon “unleash a massive framework” for how vaccines are tested and approved.

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.

In other vaccine news, Health Secretary Robert F. Kennedy Jr. has officially ordered placebo testing on new vaccines, a change that experts claim will be costly and — harkening back to polio vaccine ...

The FDA finally approved Novavax's Covid-19 vaccine, but placed restrictions on it that its two competitors in the U.S. do ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

In a world of increasing fragmentation and polarisation, the 78th World Health Assembly, starting Monday, will present itself ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...